The Wnt/β-catenin signaling pathway is important for multiple developmental processes and 2 tissue maintenance in adults. Consequently, deregulated signaling is involved in a range of 3 human diseases including cancer and developmental defects. A better understanding of the 4 intricate regulatory mechanism and effect of physiological (active) and pathophysiological 5 (hyperactive) WNT signaling is important for predicting treatment response and developing 6 novel therapies. The constitutively expressed CTNNB1 (commonly and hereafter referred to 7 as β-catenin) is degraded by a destruction complex, composed of amongst other AXIN1 and 8 GSK3. The destruction complex is inhibited during active signaling leading to β-catenin 9 stabilization and induction of β-catenin/TCF target genes. In this study we investigated the 10 mechanism and effect of β-catenin stabilization during active and hyperactive WNT signaling 11 in a combined in silico and in vitro approach. We constructed a Petri net model of Wnt/β-12 catenin signaling including main players from the plasma membrane (WNT ligands and 13 receptors), cytoplasmic effectors and the downstream negative feedback target gene AXIN2. 14 We simulated the model with active (i.e. WNT stimulation) and hyperactive (i.e. GSK3 15 inhibition) signaling, which led to the following observations: 1) A dose-and time-dependent 16 response was observed for both WNT stimulation and GSK3 inhibition. 2) The Wnt-pathway 17 activity was 2-fold higher for GSK3 inhibition compared to WNT stimulation. Both of these 18 observations were corroborated by TCF/LEF luciferase reporter assays. Using this 19 experimentally validated model we simulated the effect of the negative feedback regulator 20 AXIN2 upon WNT stimulation and observed an attenuated β-catenin stabilization. We 21 furthermore simulated the effect of APC inactivating mutations, yielding a stabilization of β-22 catenin levels comparable to the Wnt-pathway activities observed in colorectal and breast 23 cancer. Our model can be used for further investigation and viable predictions of the role of 24 Wnt/β-catenin signaling in oncogenesis and development. 25 -3 -Author Summary 26 Deregulated Wnt/β-catenin signaling is implicated in cancer and developmental defects. In 27 this study we combined in silico and in vitro efforts to investigate the behavior of 28 physiological and pathophysiological WNT signaling. We created a model of Wnt/β-catenin 29 signaling that describes the core interactions: receptor activation, inhibition of downstream 30 effectors and an important negative feedback mechanism. Simulations with the model 31 demonstrated the expected dose-and time-dependent response for both conditions, and 32 the Wnt-pathway activity was significantly higher for pathophysiological compared to 33 physiological signaling. These observations were experimentally validated, which allowed us 34 to investigate and predict the effect of the negative feedback and an inactivating cancer 35 mutation on the Wnt-pathway activity. Our model provides mechanistic insight on the 36 different conditions and can easily be extended and used to answer other questions on 37 Wnt/β-catenin signaling in the area of cancer research and regenerative medicine. 38
Introduction

39
The Wnt/β-catenin signaling pathway is crucial for regulating cell proliferation and 40 differentiation during embryonic development, while in adults it helps control tissue 41 homeostasis and injury repair in stem cell maintenance [1, 2] . Extracellular WNT ligands 42 activate signaling leading to CTNNB1 (commonly and hereafter referred to as β-catenin) 43 stabilization, nuclear translocation, interaction with TCF/LEF transcription factors [3] and 44 induction of β-catenin/TCF target genes [4] ( Fig 1B) . A critical feature of Wnt/β-catenin 45 signaling is the inhibition of a 'destruction complex' which degrades the constitutively 46 expressed β-catenin ( Fig 1A) [5]. The destruction complex consists of two scaffolding proteins, AXIN1 and adenomatous 62 polyposis coli (APC), and two kinases, casein kinase 1 (CK1) and glycogen synthase kinase 3 63 (GSK3). β-catenin is phosphorylated by CK1 and GSK3 [6, 7] and thereafter presented to the 64 proteasome for ubiquitination [8] and degradation ( Fig 1A) . Extracellular WNT binds to and 65 activates the 7 transmembrane receptor, Frizzled (FZD) [9] , and the co-receptor, lipoprotein 66 receptor-related protein (LRP5/6) [10] . The intracellular tail of FZD interacts with Dishevelled 67 (DVL) through an incompletely understood mechanism and sequesters AXIN1 to the cell 68 membrane [11] forming a so-called 'signalosome' [12] . This leads to depletion of the 69 -5 -cytoplasmic pool of the destruction complex component AXIN1, which in turn inhibits the 70 formation of the destruction complex itself ( Fig 1B) . It is not fully understood whether only 71 AXIN1 or more destruction complex components are sequestered to the cell membrane 72 during WNT signaling. Indeed, a study by Li et al. [13] showed that AXIN1 does not dissociate 73 from the other destruction complex components during WNT signaling. 74
The inhibition of the destruction complex leads to β-catenin stabilization and nuclear 75 translocation. Nuclear β-catenin interacts with TCF/LEF transcription factors [14] forming the 76 β-catenin/TCF transcriptional (co)activator complex. A collection of more than 100 genes 77 induced by β-catenin/TCF transcription is listed on the WNT homepage 78 (www.web.stanford.edu/group/nusselab/cgi-bin/wnt/) (last update: September 2015). The 79 specific subset of genes induced, however, strongly depends on tissue type and 80 developmental stage [15] . Several of these target genes are feedback regulators, where 81 AXIN2 is of particular interest. First, AXIN2 is a universal β-catenin/TCF target gene and as 82 such it is believed to faithfully report Wnt-pathway activity in multiple tissues [16, 17] GSK3 inhibits the destruction complex, which can be interpreted as similar to the effects of 106 oncogenic mutations. Several mathematical models of Wnt/β-catenin signaling have been 107 created as reviewed in [36] to facilitate these investigations. However the construction of 108 these models requires detailed information on e.g. protein concentrations and reaction 109 rates, which require large experimental efforts. Consequently, the currently available 110 models include many estimated parameters, which limits their scale of applicability [36] . On 111 the other hand, coarse-grained data on interactions and relative levels of proteins are 112 readily available, and much easier to obtain. Enabling the use of such data would greatly 113 expand the scale of applicability of modeling. With this in mind, we previously introduced a 114
Petri net modeling formalism that can utilize this type of coarse-grained data [37, 38] . 115
In this paper, we present a combined computational and experimental approach to 116 build on the investigations of the mechanism and effect of β-catenin stabilization during 117 active and hyperactive WNT signaling. We created a Petri net model of Wnt/β-catenin 118 signaling describing membrane activation by the WNT ligand, β-catenin degradation by the 119 destruction complex and the negative feedback by AXIN2. We used the model to explain 120 how active signaling upon WNT stimulation and hyperactive signaling upon GSK3 inhibition 121 -7 -leads to different levels of β-catenin stabilization. We corroborated our observations from 122 the model using data from TCF/LEF luciferase reporter assays and Western blot analysis. We 123 then used the experimentally validated model to explore plausible modes of action of β-124 catenin stabilization as a result of negative feedback by activating expression of AXIN2 upon 125 WNT stimulation, or due to APC inactivating mutations that are known to play a key role in 126 oncogenesis of colorectal and breast cancer. 127
Results
128
Modeling Wnt/β-catenin signaling 129 We created a Petri net model of Wnt/β-catenin signaling to investigate the mechanism and 130 effect of β-catenin stabilization under physiological (e.g. embryonic development) and 131 pathophysiological (e.g. cancer) conditions (Fig 2) . The model describes the interactions 132 between the core proteins in the pathway with a focus on capturing the behavior of β-133 catenin stabilization following destruction complex inhibition. Therefore the degradation of 134 β-catenin by the destruction complex is specifically in the model. Likewise, the gene 135 expressions of β-catenin (encoding β-catenin), but also of AXIN2, a negative feedback target 136 gene of the Wnt-pathway, are also specifically included in the model. Production and 137 degradation of all other proteins are assumed to have similar rates and are therefore 138 omitted, such that the token levels of these proteins remain the same throughout the 139 simulation (See Materials and Methods). AXIN1 is the only destruction complex constituent that binds to the signalosome in the 171 model. The signalosome dissociates once every 10 steps (t4) into the WNT/FZD/LRP/DVL 172 complex and AXIN1 in order to incorporate a lower dissociation-than formation-rate of the 173 signalosome. The destruction complex, which sequesters β-catenin unless WNT induces 174 -10 -signalosome formation, is formed (t5) by AXIN1, APC, CK1 and GSK3. In the model, β-catenin 175 binding to the destruction complex leads to degradation of β-catenin (t8 and t7), and the 176 destruction complex is then either reused (t7) for another round of β-catenin degradation or 177 dissociates (t8) to AXIN1, APC, CK1 and GSK3. In the model, β-catenin protein is produced 178 every step (t9) following transcription of the β-catenin gene, and either binds the 179 destruction complex (t6) or translocates to the nucleus, where it interacts with TCF/LEF (t10) 180 to activate transcription of AXIN2 (t11). Since AXIN1 and AXIN2 are functional homologs 181
[18], they are modeled as one protein entity (depicted as 'AXIN'). Further, we do not 182 distinguish between the cytoplasmic and nuclear pool of β-catenin in the model. This 183 allowed the nuclear translocation and TCF/LEF interactions to be modeled as one transition 184 (t10). 185
The initial token level of all protein places was set to 5, except for TCF/LEF, which was 186 set to 1, and β-catenin, which was set to 0. The initial token level of all protein complexes 187 was set to 0. The initial token level of the gene places, β-catenin and AXIN2, was set to 1 188
(since these genes are always presumed to be present). Most arc weights were set to 1, with 189 an exception of the arc weight from β-catenin to transition t10 (i.e. its translocation to the 190 nucleus and subsequent interaction with TCF/LEF), which was set to 3, and the arc weight 191 from t10 to β-catenin, which was set to 2. From the model point of view this means that for 192 t10 to fire, the β-catenin place needs a level of 3 tokens, but that only 1 is consumed (See Fig  193   2 ). These weights were chosen because it is generally believed that β-catenin accumulates in 194 the cytoplasm before it translocates to the nucleus and binds TCF/LEF. Parts of this initial 195 setup were changed accordingly to mimic the different conditions of Wnt/β-catenin 196 signaling simulated in this study (see below). 197 -11 -Active signaling upon WNT stimulation 198 We simulated WNT stimulation to predict the level of β-catenin stabilization during active 199 signaling. To this end we ran a series of simulations with different initial WNT token levels 200 (ranging from 0 to 5) without AXIN2 feedback (i.e. the arc weight from t11 to AXIN was set 201 to 0). As shown in Fig 3A, we observed four different β-catenin response levels depending on 202 the initial WNT token level. A flat β-catenin response was seen for WNT = 0, 1 or 2. For WNT 203 = 3, 4 or 5, we observed a delay in the initial increase of β-catenin, which eventually 204 increased linearly with a slope depending on the WNT level. To predict the level of β-catenin stabilization during hyperactive signaling by a downstream 250 perturbation, we next simulated our model upon GSK3 inhibition. We ran a series of 251 simulations with different initial GSK3 token levels (ranging from 5 to 0), where 5 initial 252 tokens represents wildtype (i.e. no Wnt-pathway activity) and 0 corresponds to complete 253 inhibition (hyperactive signaling). The simulations revealed that the response levels depend 254 on initial GSK3 token levels (see Fig 4A) . For GSK3 = 3, 4 or 5, we observed a flat β-catenin 255 response. A linear increase in β-catenin levels with a slope depending on GSK3 levels was 256 seen for GSK3 = 0, 1 or 2. This corresponds to β-catenin degradation ranging from no 257 degradation to 1 or 2 β-catenin tokens degraded per three simulation steps, respectively. 258
Consequently, β-catenin stabilization was low for GSK3 = 2, moderate for GSK3 = 1 and high 259 for GSK3 = 0. Complete GSK3 inhibition led to a stabilization of 100 β-catenin tokens. 260 -14 -To validate the coarse-grained β-catenin levels predicted by our model upon GSK3 261 inhibition, we stimulated HEK293T WOO cells with increasing concentrations of CHIR99021, 262 one of the most potent and selective GSK3 inhibitors available to date, over a broad time 263 range (3, 8 and 24 hours). The measured TCF/LEF reporter gene activity confirmed the dose-264 and time-dependent increase upon GSK3 inhibition (Fig 4B and 4C ) predicted by our model 265 ( Fig 4A) . As with the Wnt3a treatment, here we also performed a TCF/LEF reporter gene 266 assay and quantitative Western blot analysis side by side for one of the treatment conditions 267
(3 µM CHIR99021) for multiple time points. An increase in both active (i.e. non-268 phosphorylated) and total (i.e. both phosphorylated and non-phosphorylated) β-catenin is 269 apparent after 1 hour, whereas an increase in the signal of the luciferase reporter assay can 270 only be detected after 3 hours. Furthermore, the dynamic range of the Western blot analysis 271 is limited compared to the reporter gene assay, allowing us to measure at most a 4-fold 272 increase in β-catenin levels in the former, but up to a 10 4 fold increase in Wnt-pathway 273 activity in the latter (Fig 4D-4F) . We used our validated model to explore if the effect of these APC mutations might be 305 explained by different rates of destruction complex formation. We implemented the effect 306 of the APC mutations, by decreasing the rate of the destruction complex formation, ranging 307 from no production at all to production every 20, 10 and 5 steps. In Fig 5 we 
Predictions of active signaling upon WNT stimulation with AXIN2 feedback 324
In our model AXIN2 is induced by β-catenin/TCF transcription and increases the cytoplasmic 325 pool of AXIN, which under certain conditions, e.g. WNT stimulation, is the limiting factor for 326 β-catenin degradation. However, our experimental dataset obtained using Wnt3a 327 stimulation showed no obvious decrease in β-catenin levels that might be due to this 328 negative feedback (Fig 3E and 3F) . It should be noted that in this experimental setting (100 329 ng/ml Wnt3a), the Wnt-pathway is likely still activated at supra-physiological levels. 330
Moreover, the WNT ligand remains present throughout the experiment. In vivo, however, 331 physiological Wnt-pathway activation is strictly regulated both due to the WNT 332 concentration gradient and due to the tight spatio-temporal control of Wnt gene expression. 333
Under these circumstances, lower levels of Wnt/β-catenin signaling are likely to occur and, 334 as a result, part of the regulation may be due to the AXIN2 auto-inhibitory feedback loop. 335 Therefore, it may be the ratio between the WNT and AXIN2 levels that is crucial to the 336 -18 -regulatory role of AXIN2. We therefore used our model to explore the spectrum of possible 337 β-catenin stabilizations under different WNT and AXIN2 levels. We ran a series of 338 simulations with different initial WNT token levels: 3, 4 or 5, showing increased β-catenin 339 stabilization in Fig 3A, and with different AXIN2 feedback strengths: the arc weight from t11 340 to AXIN was varied from 0 for no feedback to 0.15 for maximum feedback. As shown in Fig 6,  341 we observed three different spectra of β-catenin stabilizations to the different initial WNT 342 token levels. The highest β-catenin stabilizations (solid lines in Fig 6) were identical to those 343 observed in Fig 3A (without AXIN2 feedback) . At high feedback, the β-catenin stabilization is 344 lowered, and a maximum appears after which the β-catenin level declines (dashed lines in 345 fig 6) . The lowest β-catenin stabilizations displayed three different peak responses. For the 346 peak responses, the height of the peak and the duration of the response depended on initial 347 WNT token levels. Maximal β-catenin stabilization comes later in the simulation for higher 348 initial WNT token levels. 349 Our model predicts a dose-and time dependent response for both WNT stimulation and 376 GSK3 inhibition (Figs 3A and 4A ). This is confirmed by the experimental data ( Figs 3B, 3C, 4B  377 and 4C). The main discrepancy between the simulated and the experimental data is the 378 -20 -time-delay that is predicted in response to WNT stimulation compared to GSK3 inhibition 379 (compare Fig 3A to 4A) . Indeed, activation of Wnt/β-catenin signaling is known to be a slow 380 event (unlike the activation of MAPK signaling for instance, which occurs within a matter of 381 minutes) [44] [45] [46] . However, we did not detect this delay in β-catenin accumulation by either 382 TCF/LEF luciferase reporter assay (compare Fig 3B-3D to Fig 4B-4D) or Western blot analysis 383 (compare Fig 3E and 3F to Fig 4E and 4F) . We believe this is mainly due to experimental 384 limitations. Given that a subtle increase in β-catenin protein levels can be detected 385 approximately one hour after stimulation with either Wnt3a (Fig 3E and 3F) or CHIR99021 386 ( Fig 4E and 4F) , any delay in activation of the Wnt-pathway must occur prior to that time 387 point. Detecting this delay would require assays with superior spatio-temporal resolution. 388
The delay predicted by our model upon WNT stimulation ( Fig 3A) can be explained by the 389 fact that formation of the signalosome occurs a few steps into the simulation, whereas 390 inhibition of GSK3 is a one-step event, and that the transitions for signalosome formation 391 (i.e. pathway activation) and destruction complex formation (i.e. pathway inhibition) 392 compete for AXIN1. Thus, when AXIN1 is sequestered to the plasma membrane, less 393 cytoplasmic AXIN1 is available for formation of the destruction complex. To what extent 394 these events contribute to Wnt-pathway activation under experimental conditions remains 395 unknown, owing to the absence of tools to study the exchange of AXIN1 between these two 396 pools. Our results do suggest that competition over AXIN1 between the destruction complex 397 and the signalosome may well be important also under physiological conditions. 398
The time-delay together with the continuous sequestration and dissociation of AXIN1 to 399 the signalosome leads to prediction of higher stabilization of β-catenin for complete GSK3 400 inhibition compared to maximal WNT stimulation, where the difference is almost two-fold 401 (compare Fig 4A to Fig 3A) . We observe a similar difference when measuring TCF/LEF 402 reporter gene activity: the highest concentration of CHIR99021 activates the reporter 403 approximately 10-fold higher than the highest concentration of Wnt3a tested (compare Fig  404   - 
-
4B-4D to Fig 3B-3D ). Comparing protein levels, instead of transcriptional activation, shows a 405 much smaller difference: 2-fold higher β-catenin at most when cells are stimulated with 406 CHIR99021 versus Wnt3a (compare Fig 4E and 4F to Fig 3E and 3F) . Although it is tempting 407 to conclude that this data again confirms the predictions of our model, it should be stressed 408 that the different experimental modes of Wnt-pathway activation cannot be compared 409 directly. This is because they are achieved by different molecules (i.e. purified Wnt3a versus 410 a synthetic small-molecule GSK3 inhibitor) with different intrinsic activities and chemical 411
properties such as half-life and stability in the tissue culture medium, which may greatly 412 impact on the experimental outcome. At the same time, we may speculate that the 413 observed differences reflect real differences in sensitivity of the Wnt-pathway. In this case, 414 our experimental findings might be explained by the fact that the more physiological means 415 of pathway activation by Wnt3a is more likely to be subject to negative feedback control via 416 AXIN2 induction than the more artificial perturbation by CHIR99021 inhibition of GSK3 at the 417 level of the destruction complex. 418 AXIN2 is one of the few comprehensive globally expressed WNT target genes and is 419 thought to act as a negative regulator to Wnt/β-catenin signaling [16, 17] . The degree to 420 which AXIN2 attenuates WNT signaling and the actual spatio-temporal regulatory role of 421 AXIN2 is still a topic of debate. Indeed, when we incorporate this negative feedback loop in 422 the model upon WNT stimulation, our simulations predict that Wnt-pathway activity is 423 attenuated (at certain levels of AXIN2 induction), and ultimately returns to baseline levels 424 (dashed lines in Fig 6) . Importantly, in the model the feedback from AXIN2 only negatively 425 influences stabilized β-catenin levels when AXIN1 is the limiting factor. This is the case when 426 AXIN1 is deprived from the cytoplasm by sequestration to the signalosome (i.e. upon WNT 427 stimulation). This is why we are able to observe a negative effect from the AXIN2 feedback 428 upon WNT stimulation in our model (fig 6) , but not by GSK3 inhibition (Fig 4A) or APC 429 inactivating mutations ( Fig 5) . It should be noted however, that on the timescale used for 430 -22 -the experiments, we do not observe complete feedback inhibition by AXIN2 ( Fig 3B-3F) . This 431 might be due to the relatively low level of AXIN2 induction in the cells used for these 432 experiments (data not shown) in combination with supra-physiological levels of Wnt-433 pathway activation achieved upon stimulation with purified Wnt3a. However, it could also 434 be due to the fact that AXIN1 is not the limiting factor in the cells used for this study. 435
Previously, a study of Wnt/β-catenin signaling in Xenopus laevis showed that AXIN1 is 1000-436 fold lower than the other components of the destruction complex [39] and has therefore 437 been considered the natural limiting factor. However, a recent study of Wnt/β-catenin 438 signaling in mammalian cells showed that the concentrations of the components of the 439 destruction complex were on the same range [47] . Therefore, we cannot exclude the 440 possibility that AXIN1 is not the limiting factor in the cells used for this study. Unfortunately, 441 the current experimental tools, most notably Western blot analysis of endogenous β-catenin 442 levels, are not sufficiently robust, high-throughput and sensitive enough to resolve this issue. 443
However, by using our model we were able to predict and visualize spectra of β-catenin 444 stabilization, which showed that the ratio between the WNT and AXIN2 levels are important 445 for the degree of feedback observed (Fig 6) . The two most notable observations were that, 446 for high WNT levels, a higher level of AXIN2 was needed to reach baseline β-catenin levels 447 and, for low WNT levels, a baseline β-catenin level is reached early. Based on these 448 predictions we can speculate whether the AXIN2 negative feedback only has an effect on 449 low WNT levels and whether the regulatory role of this is to insure a faster on/off switch of 450 Wnt-pathway activity. Indeed, Wnt-pathway activity shows dynamic on and off switches 451 during development [22] . Examples of these are the restriction of Wnt/β-catenin responsive 452 cells to the crypt, but not to the villus sections of the intestinal epithelium, and oscillation of 453 WNT signaling as part of the mouse segmentation clock. 454
In conclusion, our Petri net model of Wnt/β-catenin signaling provides insight on the 455 mechanisms leading to different levels of β-catenin stabilization upon WNT stimulation and 456 -23 -GSK3 inhibition corroborated by TCF/LEF luciferase assay and Western blot analysis. It 457 should be stressed that the simulations show a coarse-grained output per step and we 458 cannot directly map token levels to the relative activities in the TCF/LEF luciferase reporter 459 assay nor to the β-catenin levels measured by Western blot analysis. Furthermore, we also 460 cannot directly map a simulation step in the model to an experimental timescale. Despite 461 these limitations, our model resembles Wnt/β-catenin signaling to the extent that it 462 captures the logic of the interactions and reflects the sequence of events of pathway 463 activation and repression by various mechanisms. In this way, our model can be used to 464 simulate and predict both physiological and pathophysiological WNT signaling. Thus, this 465 modelling exercise has allowed us to study the mechanisms and effects of Wnt/β-catenin 466 signaling under different conditions, as well as the effects of protein-and pathway-467 modifications that are known to influence this pathway in many types of cancer. 468
Materials and Methods
469
Petri net modeling 470 We built a Petri net model of Wnt/β-catenin signaling describing known components, 471 actions and interactions, well established in literature, in a logical way. A Petri net consists of 472 two types of nodes, 'places' and 'transitions', and is connected by directed edges called 473 'arcs'. A place represents an entity (e.g. gene or protein), whereas a transition indicates the 474 activity occurring between the places (e.g. gene expression or complex formation). Places 475 can only link to transitions and vice versa (i.e., a Petri net is a bipartite graph). The direction 476 of the arcs is important for the flow of the network. An arc goes from an input place to a 477 transition, and from a transition to an output place. Places contain 'tokens', indicating the 478 availability of the corresponding entity, while arcs have a weight, denoting the amount of 479 tokens to consume from an input place or to produce to an output place. If the token levels 480 -24 -of all input places of a transition fulfill the requirement of (i.e. are equal to or higher than) 481 the weights of the respective arcs, the transition is enabled. Only enabled transitions can be 482 executed, leading to transfer (consumption/production) of tokens between places. Note that 483 if two (or more) enabled transitions share an input place, they may be in competition if 484 available token levels do not allow simultaneous execution of both (or all). In our model, 485 AXIN, β-catenin and the destruction complex with β-catenin bound, are each input places for 486 two transitions (t3/t5, t6/t10 and t7/t8, respectively). 487
Gene expression is modeled such that one arc goes from the gene-place to the 488 transcriptional-transition, one arc goes from the transcriptional-transition to the gene-place, 489 and one arc goes from the transcriptional-transition to the protein-place. When the 490 transcriptional-transition of a gene is enabled a token is produced both in the protein-place 491 and in the gene-place itself. This way the token can be reused for another round of gene 492 expression, reflecting the fact that the gene (DNA) is needed, but is not consumed during 493 expression. 494
